Spark Investment Management LLC Buys Shares of 48,400 Natus Medical Inc (BABY)
Spark Investment Management LLC acquired a new position in shares of Natus Medical Inc (NASDAQ:BABY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 48,400 shares of the medical equipment provider’s stock, valued at approximately $1,669,000. Spark Investment Management LLC owned about 0.14% of Natus Medical as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Natus Medical during the first quarter worth $124,000. US Bancorp DE boosted its holdings in shares of Natus Medical by 81.2% during the first quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 2,125 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Natus Medical by 46.3% during the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock worth $161,000 after purchasing an additional 1,478 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new stake in shares of Natus Medical during the second quarter worth $201,000. Finally, Profund Advisors LLC acquired a new stake in shares of Natus Medical during the first quarter worth $218,000. Institutional investors and hedge funds own 96.63% of the company’s stock.
BABY stock opened at $36.20 on Friday. Natus Medical Inc has a 52-week low of $28.00 and a 52-week high of $43.60. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.19 and a current ratio of 2.99. The firm has a market cap of $1.22 billion, a PE ratio of 24.97 and a beta of 0.58.
BABY has been the topic of several analyst reports. BidaskClub cut Natus Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 28th. ValuEngine cut Natus Medical from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Finally, Zacks Investment Research cut Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 27th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $44.33.
In related news, Director Robert A. Gunst sold 9,100 shares of the stock in a transaction on Friday, July 27th. The stock was sold at an average price of $34.11, for a total value of $310,401.00. Following the transaction, the director now directly owns 54,982 shares of the company’s stock, valued at approximately $1,875,436.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ken Ludlum sold 8,000 shares of the stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $36.89, for a total value of $295,120.00. Following the completion of the transaction, the director now directly owns 98,957 shares in the company, valued at $3,650,523.73. The disclosure for this sale can be found here. Insiders sold a total of 29,940 shares of company stock worth $1,050,555 over the last ninety days. Corporate insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Story: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.